Eli Lilly and Company $LLY Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 651 shares of the company’s stock after selling 87 shares during the period. Wedge Capital Management L L P NC’s holdings in Eli Lilly and Company were worth $507,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Busey Bank grew its holdings in Eli Lilly and Company by 2.5% during the 2nd quarter. Busey Bank now owns 24,376 shares of the company’s stock worth $19,002,000 after acquiring an additional 601 shares in the last quarter. Silver Oak Securities Incorporated grew its position in shares of Eli Lilly and Company by 3.2% in the 2nd quarter. Silver Oak Securities Incorporated now owns 2,873 shares of the company’s stock valued at $2,239,000 after buying an additional 89 shares during the last quarter. CX Institutional grew its position in shares of Eli Lilly and Company by 6.4% in the 2nd quarter. CX Institutional now owns 28,967 shares of the company’s stock valued at $22,580,000 after buying an additional 1,744 shares during the last quarter. CMH Wealth Management LLC grew its position in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. CMH Wealth Management LLC now owns 12,462 shares of the company’s stock valued at $9,715,000 after buying an additional 165 shares during the last quarter. Finally, Pinnacle Bancorp Inc. grew its position in shares of Eli Lilly and Company by 1.1% in the 2nd quarter. Pinnacle Bancorp Inc. now owns 5,364 shares of the company’s stock valued at $4,181,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Eli Lilly and Company Stock Down 1.0%

Shares of NYSE:LLY opened at $747.29 on Wednesday. The stock has a market cap of $707.27 billion, a P/E ratio of 48.84, a P/E/G ratio of 1.05 and a beta of 0.47. The firm has a fifty day moving average price of $736.98 and a 200 day moving average price of $768.86. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 in the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.